A meta-analysis comparing bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome was published on September 25, 2026. The publication, titled "Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome: A meta-analysis," appeared in the journal Medicine. Bivalirudin is an approved compound. The publication is indexed under PubMed ID 42798052. No specific findings, outcomes, or results from the meta-analysis are detailed in this report. Readers interested in the comparison between these two agents in the PCI setting can consult the full publication for its methodology and conclusions. This item reports solely on the existence and bibliographic details of the new publication, including its title, journal, and publication date. For additional background on bivalirudin, including its approved uses and general profile, readers can refer to the compound overview.
New Meta-Analysis Publishes on Bivalirudin vs Heparin in PCI
See the full bivalirudin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42798052/